Securing Research and Development Funding Through Partnership Revenue, New Share Issuances and Other Sources
First written in FY2016. 31 of 42 entries say "Advanced", first in FY2017. Latest entry: 2026-10-14.
12 other companies' latest entry also says "Advanced".
- FY2026No full-year cash inflow from financing activitiesAnnual report
「Cash flows from financing activities showed no material change (an increase of ¥1,748,929 thousand in the previous fiscal year).」
The company maintains its policy of securing research and development funding through partnership income and financing, but there was no cash inflow from financing activities during the fiscal year. - FY2026-H1No financing in the first halfAnnual report
「No cash flow from financing activities occurred. (The same period of the previous year saw an increase of ¥1,150.682 million.)」
The company has maintained its policy of securing R&D funding through financing and other means, but during the current interim accounting period there were no cash inflows from financing activities, and R&D expenditures were funded mainly with cash on hand. - FY2025AdvancedAnnual report
「Net cash provided by financing activities increased by ¥1,748.929 million, due to proceeds from the issuance of shares upon exercise of stock acquisition rights, compared with an increase of ¥1,538.270 million in the previous fiscal year.」
The company raised ¥1,748.929 million through the issuance of shares upon exercise of stock acquisition rights, advancing measures to secure R&D funding through direct financing compared with the previous fiscal year. - FY2025-H1AdvancedAnnual report
「Net cash provided by financing activities increased by ¥1,150.682 million, due to proceeds from the conversion of stock acquisition rights into shares and other items, compared with an increase of ¥1,539.296 million in the same period of the previous year.」
The company secured a ¥1,150.682 million increase in financing cash flow during the current interim accounting period through the conversion of stock acquisition rights into shares and other transactions, funding R&D expenses through direct financing. - FY2024AdvancedAnnual report
「Net cash provided by financing activities increased by ¥1,538.270 million, due to proceeds from the issuance of shares upon exercise of stock acquisition rights and other items, compared with an increase of ¥2,272.621 million in the previous fiscal year.」
The company secured a ¥1,538.270 million increase in financing cash flow during the fiscal year through the exercise of stock acquisition rights and other transactions, continuing to raise funds through direct financing. - FY2024-Q3AdvancedAnnual report
「In net assets, retained earnings decreased by ¥553.880 million due to the recording of a quarterly net loss. At the same time, the exercise of stock acquisition rights and the issuance of new shares as restricted stock compensation each increased capital stock and capital surplus by ¥808.078 million.」
The exercise of stock acquisition rights and the issuance of new shares as restricted stock compensation increased capital stock and capital surplus by ¥808.078 million each, advancing direct financing to secure R&D funding. - FY2024-Q2AdvancedAnnual report
「Net cash provided by financing activities increased by ¥1,539.296 million, due to proceeds from the conversion of stock acquisition rights into shares and other items, compared with an increase of ¥1,791.195 million in the same quarter of the previous year.」
The company secured a ¥1,539.296 million increase in financing cash flow during the six-month period through the conversion of stock acquisition rights into shares and other transactions, advancing measures to fund R&D directly through financing. - FY2024-Q1AdvancedAnnual report
「Proceeds from the exercise of rights during the relevant quarterly accounting period (¥ millions): 1,252」
The company raised ¥1,252 million during the first quarter through the exercise of the 19th Series Stock Acquisition Rights. Capital stock and capital surplus also each increased by ¥630.038 million, advancing direct financing to secure R&D funding. - FY2023AdvancedAnnual report
「Net cash provided by financing activities increased by ¥2,272.621 million, due to proceeds from the exercise of stock acquisition rights and the issuance of new shares and stock acquisition rights, among other items, compared with an increase of ¥282.751 million in the previous fiscal year.」
The company secured a ¥2,272.621 million increase in financing cash flow during the fiscal year through the exercise of stock acquisition rights and the issuance of new shares and stock acquisition rights. - FY2023-Q3AdvancedAnnual report
「In net assets, retained earnings decreased by ¥711.629 million due to the recording of a quarterly net loss. At the same time, the exercise of stock acquisition rights increased capital stock and capital surplus by ¥1,107.047 million each, while stock acquisition rights decreased by ¥22.706 million.」
The exercise of stock acquisition rights increased capital stock and capital surplus by ¥1,107.047 million each, advancing the implementation of direct financing to secure R&D funding. - FY2023-Q2AdvancedAnnual report
「Net cash provided by financing activities increased by ¥1,791.195 million, due to proceeds from the conversion of stock acquisition rights into shares, compared with an increase of ¥148.390 million in the same quarter of the previous year.」
The company secured ¥1,791.195 million in financing cash flow during the six-month period through the conversion of stock acquisition rights into shares and other transactions. Following the decision to proceed directly to the Phase 3 trial without conducting Stage 2 of the Phase 2 trial, the use of proceeds was consolidated and changed to cover the initial part of the Phase 3 trial. - FY2023-Q1AdvancedAnnual report
「Proceeds from the exercise of rights during the relevant quarterly accounting period (¥ millions): 1,173 All remaining 17th Series Stock Acquisition Rights were exercised between 1 October 2022 and 11 November 2022.」
The company raised ¥1,173 million during the quarter through the exercise of the 17th Series Stock Acquisition Rights, and all remaining rights had been exercised by the filing date. In addition, the use of proceeds for Part 1 of the CBP501 Phase 3 trial or Stage 2 of the Phase 2 trial was changed from ¥1,200 million to ¥817 million. - FY2022AdvancedAnnual report
「Net cash provided by financing activities increased by ¥282.751 million, due to proceeds from the issuance and exercise of stock acquisition rights and expenditures for the acquisition and cancellation of the company’s own stock acquisition rights and the partial repurchase and cancellation of convertible bonds with stock acquisition rights, among other items, compared with an increase of ¥728.800 million in the previous fiscal year.」
The company secured ¥282.751 million in financing cash flow through the issuance and exercise of stock acquisition rights and other transactions. It also raised funds through the 17th Series Stock Acquisition Rights and refinanced and partially repurchased and cancelled convertible bonds, advancing the securing of funds through direct financing and the review of the use of proceeds. - FY2022-Q3AdvancedAnnual report
「Number of bonds with stock acquisition rights subject to exercise price adjustment clauses, etc., exercised during the relevant quarterly accounting period (units): 10,288 Number of shares issued upon exercise during the relevant quarterly accounting period (shares): 1,028,800 Proceeds from exercises during the relevant quarterly accounting period (¥ millions): 213」
The company raised ¥213 million during the third-quarter accounting period through the exercise of stock acquisition rights and other instruments, issuing 1,028,800 shares. The structure of securing R&D funding through partnership income and financing remains in place. - FY2022-Q2Deletion of use of proceeds and cancellation of stock acquisition rightsAnnual report
「In connection with this cancellation, the use of proceeds and planned expenditure period will be changed (deleted).」
The company acquired and cancelled the unexercised portion of the 15th Series Stock Acquisition Rights, representing 342,516 shares, and deleted the planned allocation to working capital from July to December 2023. Financing cash flow increased by ¥148.390 million during the six-month period. - FY2022-Q1AdvancedAnnual report
「As the exercise of the 17th Series Stock Acquisition Rights is expected to precede that of the 15th Series Stock Acquisition Rights, the planned timing of the above expenditure from the 15th Series Stock Acquisition Rights will be changed from “working capital from July to December 2023” to a later period.」
The funding plan now assumes that the issuance and exercise of the 17th Series Stock Acquisition Rights will precede those of the 15th Series Stock Acquisition Rights, and the timing for allocating the 15th Series Stock Acquisition Rights to working capital was changed from July to December 2023. Proceeds from exercises during the quarter were ¥28 million, bringing the cumulative total to ¥736 million. - FY2021AdvancedAnnual report
「Net cash provided by financing activities increased by ¥728.800 million, due to proceeds from the issuance and exercise of stock acquisition rights, among other items, compared with an increase of ¥901.659 million in the previous fiscal year.」
The company secured a ¥728.800 million increase in financing cash flow through the issuance and exercise of stock acquisition rights. The use of proceeds was reallocated to costs including Stage 1 of the CBP501 Phase 2 trial, while preparations for the CBP-A08 preclinical trial were discontinued. - FY2021-Q3AdvancedAnnual report
「Proceeds from the exercise of rights during the relevant quarterly accounting period (¥ millions): 356」
The company raised ¥356 million during the third-quarter accounting period through the exercise of stock acquisition rights, advancing the securing of R&D funding through direct financing. - FY2021-Q2AdvancedAnnual report
「Net cash provided by financing activities increased by ¥136.110 million, due to proceeds from the issuance of stock acquisition rights and the issuance of shares upon exercise of stock acquisition rights, compared with an increase of ¥754.146 million in the same quarter of the previous year.」
The company secured a ¥136.110 million increase in financing cash flow during the six-month period through the issuance and exercise of stock acquisition rights. During the second-quarter accounting period, 252,800 shares were issued and ¥112 million was raised, and the use of proceeds was also reviewed. - FY2021-Q1AdvancedAnnual report
「At a Board of Directors meeting held on 5 November 2020, the company resolved to issue the 16th Series Stock Acquisition Rights through a third-party allotment, as follows.」
The company resolved to issue the 16th Series Stock Acquisition Rights, putting in place additional financing earmarked for the costs of the next clinical trial for CBP501 and working capital. The company also raised ¥14 million during the first quarter through the exercise of stock acquisition rights. - FY2020AdvancedAnnual report
「Net cash provided by financing activities increased by ¥901.659 million, due to proceeds from the issuance of unsecured convertible bonds with stock acquisition rights and the issuance and exercise of stock acquisition rights, among other items, compared with an increase of ¥683.192 million in the previous fiscal year.」
The company secured a ¥901.659 million increase in financing cash flow during the fiscal year through the issuance of unsecured convertible bonds with stock acquisition rights and the issuance and exercise of stock acquisition rights. - FY2020-Q3RestatedAnnual report
「Regarding negative cash flow from operating activities during the upfront investment period, the company plans to secure operating cash flow through upfront license payments, milestone payments and reimbursements of research and development expenses from new alliance partners obtained through its ongoing alliance activities, while also raising funds and taking other measures at an appropriate time as necessary and offsetting the shortfall with positive cash flow from financing activities.」
The company has reaffirmed its policy of securing funding for the R&D period through partnership-related upfront payments, milestone payments, reimbursement of R&D expenses and other income, together with financing as necessary. - FY2020-Q2AdvancedAnnual report
「Net cash provided by financing activities increased by ¥754.146 million, due to proceeds from the issuance of bonds and stock acquisition rights and expenditure for the purchase of treasury shares, compared with an increase of ¥210.080 million in the same quarter of the previous year.」
The company carried out the issuance of bonds and stock acquisition rights and secured a ¥754.146 million increase in financing cash flow during the six-month period. - FY2020-Q1AdvancedAnnual report
「Pursuant to a resolution of the Board of Directors meeting held on 10 October 2019, the company issued the following securities through a third-party allotment: the 15th Series Stock Acquisition Rights and the 3rd Series Unsecured Convertible Bonds with Stock Acquisition Rights.」
After the end of the fiscal year, the company raised funds through the 15th Series Stock Acquisition Rights for 558,600 shares and the 3rd Series Unsecured Convertible Bonds with Stock Acquisition Rights, with total issue proceeds of ¥749,994,000. The proceeds were earmarked for the CBP501 clinical trial, working capital and preparations for CBP-A8 preclinical trials. - FY2019AdvancedAnnual report
「Net cash provided by financing activities increased by ¥683.192 million, due to proceeds from the issuance of unsecured convertible bonds with stock acquisition rights and the issuance and exercise of stock acquisition rights, compared with an increase of ¥7.542 million in the previous fiscal year.」
The company secured a ¥683.192 million increase in financing cash flow during the fiscal year through the issuance and exercise of unsecured convertible bonds with stock acquisition rights and stock acquisition rights. - FY2019-Q3AdvancedAnnual report
「Proceeds from the exercise of rights during the relevant quarterly accounting period (¥ millions): 100」
In addition to raising ¥100 million during the quarter through the exercise of the 14th Series Stock Acquisition Rights, capital stock and capital surplus also increased through the conversion of convertible bonds with stock acquisition rights and other transactions, advancing the securing of funds through direct financing. - FY2019-Q2AdvancedAnnual report
「Net cash provided by financing activities increased by ¥210.080 million, due to proceeds from the issuance of bonds and stock acquisition rights, compared with an increase of ¥7.442 million in the same quarter of the previous year.」
The company recorded ¥210.080 million in cash inflows from the issuance of bonds and stock acquisition rights, advancing the securing of R&D funding through direct financing. - FY2019-Q1AdvancedAnnual report
「During the current first quarter accounting period, stock acquisition rights relating to bonds with stock acquisition rights subject to exercise price adjustment clauses were exercised as follows.」
During the quarter, 10 stock acquisition rights were exercised and 100,000 shares were issued. As a result, issued shares, capital stock and capital surplus increased, advancing the implementation of the financing plan. - FY2018AdvancedAnnual report
「Pursuant to a resolution of the Board of Directors meeting held on 2 July 2018, the company issued the following securities through a third-party allotment: the 2nd Series Unsecured Convertible Bonds with Stock Acquisition Rights and the 14th Series Stock Acquisition Rights. Total issue price: ¥209,220,000」
The company resolved to issue and carried out the issuance of convertible bonds with stock acquisition rights and stock acquisition rights, with the proceeds to be used for the CBP501 Phase 1b expansion-cohort trial, basic research expenses and preparations for CBP-A08 preclinical trials, thereby putting in place a specific direct-financing plan. The issuance took place after the end of the fiscal year. - FY2018-Q3RestatedAnnual report
「Regarding negative cash flow from operating activities during the upfront investment period, the company plans to secure operating cash flow through upfront license payments, milestone payments and reimbursements of research and development expenses from new alliance partners obtained through its ongoing alliance activities, while also raising funds and taking other measures at an appropriate time as necessary and offsetting the shortfall with positive cash flow from financing activities.」
The company has reaffirmed its policy of securing funding for the period of upfront investment through partnership-related upfront payments, milestone payments, reimbursement of R&D expenses and other income, together with financing as necessary. - FY2018-Q2SoftenedAnnual report
「Although the costs related to starting the Phase 1b trial can be covered with cash on hand, funding for development costs through the end of the clinical trial, as well as ordinary R&D expenses and total selling, general and administrative expenses, remains uncertain. If the company is unable to generate cash flow through an early-stage partnership or other means, it will need to consider raising new funds.」
While the costs of starting the Phase 1b trial can be covered with cash on hand, funding for development costs and other expenses through the end of the trial remains uncertain, indicating a conditional funding plan under which additional financing will be required if partnership income is not received. - FY2018-Q1AdvancedAnnual report
「During the current first quarter accounting period, stock acquisition rights relating to bonds with stock acquisition rights subject to exercise price adjustment clauses were exercised as follows.」
During the first quarter, 20 stock acquisition rights were exercised and 2,000 shares were issued, generating ¥1 million in proceeds. The structure of securing R&D funding through partnership income and additional financing remains in place. - FY2017AdvancedAnnual report
「Net cash provided by financing activities increased by ¥380.828 million, due to proceeds from the exercise of stock acquisition rights.」
The company raised ¥380.828 million during the fiscal year through the exercise of the 10th Series Stock Acquisition Rights. Meanwhile, the structure requiring partnership income and additional financing to cover future development costs and other expenses remains in place. - FY2017-Q3Assumed exercise of the 10th Series Stock Acquisition RightsAnnual report
「Although the costs related to starting the Phase 1b trial can be covered with cash on hand, the company assumes that funding for development costs through the end of the clinical trial, as well as ordinary R&D expenses and total selling, general and administrative expenses, will be raised through the exercise of the currently outstanding 10th Series Stock Acquisition Rights. If these stock acquisition rights are not exercised, the company will need to consider raising new funds.」
While the costs of starting the Phase 1b trial can be covered with cash on hand, the company has finalized a funding plan that assumes the exercise of the 10th Series Stock Acquisition Rights to cover development costs and other expenses through the end of the trial. - FY2017-Q1RestatedAnnual report
「Regarding negative cash flow from operating activities during the upfront investment period, the company plans to secure operating cash flow through upfront license payments, milestone payments and reimbursements of research and development expenses from new alliance partners obtained through its ongoing alliance activities, while also raising funds and taking other measures at an appropriate time as necessary and offsetting the shortfall with positive cash flow from financing activities.」
The company has reaffirmed its policy of securing R&D funding through partnership-related upfront payments, milestone payments and other income, together with financing as necessary. - FY2016First statedAnnual report
「To address the growing funding needs associated with progress in each development project and expansion of the development portfolio, as well as to strengthen its anticancer drug development capabilities, the company is pursuing activities aimed at establishing strategic alliances with pharmaceutical companies for each project. It also plans to raise funds through the issuance of new shares and other means at an appropriate time as necessary.」
The company has stated its policy of funding research and development expenses through alliance revenue from pharmaceutical companies and financing activities such as the issuance of new shares.